|
| Press Releases |
|
 |
|
| Tuesday, June 8, 2021 |
|
|
FDA grants accelerated approval for ADUHELM as the first and only Alzheimer's disease treatment to address a defining pathology of the disease |
| Biogen and Eisai, Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for ADUHELM (aducanumab-avwa) as the first and only Alzheimer's disease treatment to address a defining pathology of the disease by reducing amyloid beta plaques in the brain. more info >> |
|
|
Eisai: New Data on LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus Sunitinib |
| Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. announced new investigational data from the pivotal Phase 3 CLEAR(Study 307)/KEYNOTE-581 trial, which evaluated the combinations of LENVIMA. more info >> |
|
| Wednesday, June 2, 2021 |
|
|
エーザイ、人事異動（2021年6月1日付）を発表 |
| エーザイ株式会社は本日、人事異動（2021年6月1日付）を発表しました。 more info >> |
|
| Monday, May 31, 2021 |
|
|
Eisai and ITO EN Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia |
| Eisai Co., Ltd. and ITO EN, LTD. announced today that both parties have entered into a business alliance agreement concerning the initiatives for supporting people living with and preventing dementia with the aim of realizing a healthy and long-lived society. more info >> |
|
|
エーザイと伊藤園による認知症との共生と予防に向けた業務提携について |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫、以下 エーザイ）と株式会社伊藤園（本社：東京都、代表取締役社長：本庄大介、以下 伊藤園）は、本日、健康長寿社会の実現をめざし、認知症との共生と予防に向けた取り組みに関する業務提携契約を締結したことをお知らせします。 more info >> |
|
| Thursday, May 20, 2021 |
|
|
エーザイ、米国臨床腫瘍学会年次総会においてがん領域の開発品・製品に関する最新知見を発表 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、2021年6月4日～8日にバーチャル形式で開催される「米国臨床腫瘍学会（American Society of Clinical Oncology：ASCO）年次総会」（2021 ASCO Annual Meeting*）において、当社が創製したレンバチニブメシル酸塩（マルチキナーゼ阻害剤、製品名： 「レンビマ(R)」、以下 レンバチニブ）、エリブリンメシル酸塩（ハリコンドリン系微小管ダイナミクス阻害剤、製品名： 「ハラヴェン(R)」、以下 エリブリン）など、がん領域の開発品や製品に関する最新知見を発表することをお知らせします。 more info >> |
|
|
Eisai to Present Data on Oncology Pipeline and Products at ASCO Annual Meeting |
| Eisai Co., Ltd. announced today that the latest data regarding its oncology pipeline and products including in-house discovered lenvatinib mesylate and eribulin mesylate will be presented at the American Society of Clinical Oncology (2021 ASCO Annual Meeting*), to be held virtually from June 4 to 8, 2021. more info >> |
|
| Wednesday, May 19, 2021 |
|
|
エーザイ、末梢性T細胞リンパ腫および皮膚T細胞性リンパ腫に係る効能効果の抗がん剤「レミトロ(R)点滴静注用300ug」を新発売 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫、以下 エーザイ）は本日、日本において「再発又は難治性の末梢性T細胞リンパ腫」、「再発又は難治性の皮膚T細胞性リンパ腫」を効能効果とする、抗がん剤「レミトロ(R)点滴静注用300ug」（一般名：デニロイキン ジフチトクス（遺伝子組換え））を新発売したことをお知らせします。本剤は、2021年3月23日に製造販売承認を取得し、5月19日に薬価収載されました。 more info >> |
|
|
Anticancer Agent "Remitoro Intravenous Drip Infusion 300 microgram" (Denileukin Diftitox (Genetical Recombination)) Launched in Japan |
| Eisai Co., Ltd. announced today that it has launched the anticancer agent ?Remitoro? for Intravenous Drip Infusion 300 microgram (Denileukin Diftitox (Genetical Recombination)) with the indications of relapsed or refractory Peripheral T-cell Lymphoma (PTCL) and relapsed or refractory Cutaneous T-cell Lymphoma (CTCL), in Japan. more info >> |
|
| Friday, May 14, 2021 |
|
|
Eisai and National Cancer Center Commence Joint Research and Development Project |
| Eisai Co., Ltd. and the National Cancer Center Japan announced today that both parties have entered into a joint research and development (R&D) agreement concerning "Basic research on the drug discovery and development to accelerate development of anticancer drugs in treatment of patients with rare cancers and refractory cancers", and that research activities have commenced. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
華住公佈2024年第一季度財報 收入增長17.8%优于预期
May 17, 2024 22:39 HKT/SGT
|
|
|
H World Group Limited Reports Q1 2024 Financial Results with 17.8% Revenue Growth, Surpassing Expectation
May 17, 2024 22:29 HKT/SGT
|
|
|
Top executives from SDAIA, Saudi Aramco, Almarai, Saudi Pro League & many others coming to speak at Smart Data & AI Summit
May 17, 2024 20:09 HKT/SGT
|
|
|
卓悦集团附属公司与“湖南广电芒果超媒”旗下“快乐购”签署战略合作备忘录
May 17, 2024 20:00 HKT/SGT
|
|
|
卓悅集團附屬公司與「湖南廣電芒果超媒」旗下「快樂購」簽署戰略合作備忘錄
May 17, 2024 19:43 HKT/SGT
|
|
|
Raytech Holding: Making Nasdaq Debut as It Pioneers Personal Care Electrical Appliances in a Booming Market
May 17, 2024 18:00 HKT/SGT
|
|
|
中信国际电讯CPC守正创新 AI创新方案喜迎两大奖
May 17, 2024 17:04 HKT/SGT
|
|
|
中信國際電訊CPC守正創新 AI創新方案喜迎兩大獎
May 17, 2024 16:55 HKT/SGT
|
|
|
CITIC Telecom CPC's Innovation Excellence Honored with 2 Innovation Awards
May 17, 2024 16:37 HKT/SGT
|
|
|
London Climate Technology Show 2024 Returns For Third Edition at ExCeL London
May 17, 2024 15:48 HKT/SGT
|
|
|
Sri Trang (SET: STA) announces delivery of EUDR rubber to customers
May 17, 2024 15:00 HKT/SGT
|
|
|
Sri Trang (SET: STA) announces delivery of EUDR rubber to customers
May 17, 2024 15:00 HKT/SGT
|
|
|
富士通、論理推論を可能とする大規模言語モデルの研究開発が「GENIAC」に採択
May 17, 2024 14:00: JST
|
|
|
Fujitsu chosen for GENIAC project, starts development of large language models for logical reasoning
May 17, 2024 14:03 JST
|
|
|
NEC Leverages RISE with SAP and AI to Build Business AI in Move to the Cloud
May 17, 2024 11:19 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
